Positron emission tomography (PET) is a molecular imaging method that provides complementary information to anatomic imaging by CT or MRI Fluorine-18-deoxyglucose (FDG) PET/CT is valuable for Detection of selected primary tumors, Detection of distant metastases, and the Detection of tumor recurrence PET/CT is used for monitoring response to therapy and, because PET changes are relatively rapid compared to tumor size, clinicians may modify the course of treatment relatively soon after initiation of therapy Positron emission tomography (PET) is a molecular imaging method that images the human body non-invasively from a functional, biochemical perspective. PET is extraordinarily sensitive and can detect minute (femtomolar)
. Axial (top) and coronal (bottom) images from PET/CT scan. PET images are on the left, CT images in the center, and PET/CT fusion images on the right. PET images show intense uptake in the descending colon corresponding to a soft tissue density that by CT criteria is not distinguishable from fecal contents. Endoscopy and subsequent surgery confirmed that this was an adenocarcinoma of the colon, in this case an incidental finding on a study performed for another indication.
and continued CT follow-up may still be required. As a general rule, pulmonary nodules must be at least 8 mm in diameter for meaningful evaluation because PET imaging does not have sufficient resolution to successfully image nodules that are smaller than this.
PET/CT using contrast enhanced diagnostic CT is critical for the initial evaluation of head and neck tumors, where the complexity of the surrounding anatomy, together with relatively high rates of physiological uptake in tissues such as brown fat, salivary glands, vocal cords, and skeletal muscle, pose challenges to the accuracy of diagnosis and staging.
FDG-PET is commonly employed in the initial assessment of a wide variety of common malignancies, but PET imaging may not demonstrate small tumor foci. In the breast, for example, FDG is taken up relatively rapidly into dense breast tissue and the image contrast is not sufficient to detect small (<5 mm) tumors. Therefore, the sensitivity of detection of breast lesions <5 mm has been reported to be 53%, although those >20 mm are detected with a sensitivity of 92%. FDG-PET is not recommended for staging of axillary lymph nodes in breast cancer because PET is not sensitive enough to detect micrometastases in lymph nodes that are not pathologically enlarged. This is a general principle of PET imaging. For example, in melanoma patients, FDG-PET detected 100% of lymph node metastases ≥10 mm, 83% of metastases 6 10 mm, and 23% of metastases ≥5 mm. It is also important to realize that inflammatory reactive lymph nodes may show increased FDG uptake, so biopsy of PET-positive lymph nodes is sometimes needed to confirm the presence of malignancy.
There is a relatively short list of tumors for which PET imaging is generally not useful. In prostate cancer, FDG-PET is not sufficiently accurate because these tumors are often not FDG avid. Intense excretion of tracer by the kidneys similarly makes evaluation of bladder and renal cancers very difficult. The inclusion of PET/CT in the diagnostic work-up of patients increases the accuracy of staging and leads to more appropriate management. For example, in lung cancer, PET/CT has been shown to have additional value over PET alone for the detection of extrathoracic metastases, such as those in the intestine, liver, adrenal gland, or skeleton.
With more accurate staging, fewer patients undergo futile operations and the overall costs of caring for lung cancer patients is lower. In addition, PET imaging is useful for planning for radiation therapy because it can distinguish between tumor and surrounding reactive normal tissue.
PET has been shown to be sensitive for the detection of nodal and extranodal manifestations of both Hodgkins and non-Hodgkins lymphoma and has become an important modality for the development of treatment strategy. PET/CT is also commonly used for the detection of metastatic disease in a number of other primary cancers, including colorectal and esophageal cancers and melanoma. 
PET Applications for Subsequent Treatment Strategy

PET/CT Examination Procedure
All current PET scans at the MGH are performed on a hybrid PET/CT scanner. The PET scan requires the use of a very low dose CT acquisition to allow attenuation correction and anatomic localization. If desired, standard diagnostic CT imaging can be performed at the conclusion of PET imaging as part of the same examination, and can be acquired using intravenous contrast. All MGH Imaging hybrid PET scanners have 64 slice CT scanners that provide high quality images comparable to those done on any other CT device. If a patient needs both diagnostic CT imaging and PET imaging, the diagnostic CT scans should be scheduled as part of the PET/CT study. Acquiring diagnostic CT scans at the same sitting as the PET study allows better image registration, improving diagnostic confidence, and optimizes patient convenience. If recent diagnostic CT images have been performed, the PET/CT scan can be scheduled using only low dose attenuation-correction CT, without acquiring any diagnostic CT images.
Patients are routinely asked to fast for 4-6 hours prior to the examination. Water is permitted but no sweetened beverages. Diabetic patients should fast for 4 hours before the study, and should eat and take their insulin just prior to fasting. If the patient is on an IV, there should be no glucose in the IV solution in the hours preceding the scan.
This is necessary to minimize the amount of insulin circulating in the blood and maximize FDG uptake into the metabolically active cells. All patients will have a blood glucose level measured before the scan. In a diabetic patient, a blood glucose level below 200 mg/100ml is acceptable. Above that level, the scan will be performed only if the referring physician does not believe that it is possible for the patient to lower his or her glucose level.
Patients receive an injection of 18F-FDG about an hour before the start of imaging to allow time for metabolic uptake of the tracer. During the wait time, physical activity or repetitive movement should be avoided to minimize uptake into the muscles.
The examination starts with low radiation-dose non-contrast transmission CT scan, which provides data to correct for attenuation for the PET scan. Immediately after that, the PET scan is performed while the patient remains in the same position. Depending on the size of the patient, the PET scan takes about 25-35 minutes for a routine wholebody scan, which entails imaging of the neck, chest, abdomen, and pelvis. After the PET scan is complete, intravenous contrast is administered to the patient for a standard diagnostic CT scan, if this is performed.
The radiation exposure for a PET/CT scan is about 1.4 mSv for a whole body low-dose attenuation correction scan, 16.2 mSv for a whole body (neck/chest/abdomen/pelvis) diagnostic CT scan, and about 16 mSv from the injection of 18F (15 mCi in an average sized patient). 18F has a half-life of 109 minutes and is effectively fully decayed within a few hours of administration.
PET/CT Image Interpretation
All PET/CT studies at the MGH are interpreted by a nuclear medicine specialist and a radiologist specializing in the relevant anatomy. Initial interpretations are performed separately and multidisciplinary conferences are performed twice each day. This approach results in a coherent interpretation, in which a review of the CT findings can initiate a second look by a nuclear medicine specialist, or vice versa. For example, small diffuse tumors can be overlooked in a CT examination but readily seen by PET.
While multidisciplinary interpretations can result in more accurate diagnoses, final reports may not be available the same day as the PET/CT examination and it is not possible to perform "wet reads". If necessary, there may be an expedited review without a multidisciplinary conference. However, Mass General Imaging recommends that patients do not schedule a PET/CT on the same day as an office examination.
Scheduling
Appointments can be scheduled by calling 617-724-9729 or through the Radiology Order Entry system, http://mghroe/. PET/CT is available at the main campus and at the Mass General Imaging Center in Chelsea.
A PET scan can be requested without a diagnostic CT (a low-dose CT will be necessary for attenuation correction).
This can be appropriate if a diagnostic CT has been performed recently.
Further Information
For more information about PET/CT, please contact, Edwin L. Palmer, MD, Director, Clinical Nuclear Medicine and Molecular Imaging, Mass General Hospital, 617-726-8350.
